

Resource Summary Report

Generated by [NIF](#) on Sep 16, 2026

A-172

RRID:CVCL_0131

Type: Cell Line

Proper Citation

RRID:CVCL_0131

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0131

Proper Citation: RRID:CVCL_0131

Description: Cell line A-172 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Glioblastoma

Defining Citation: [PMID:77569](#), [PMID:212188](#), [PMID:450131](#), [PMID:833871](#), [PMID:1255758](#), [PMID:1385192](#), [PMID:3518877](#), [PMID:3675803](#), [PMID:3759084](#), [PMID:4357758](#), [PMID:6173755](#), [PMID:6220172](#), [PMID:6256643](#), [PMID:6260907](#), [PMID:6652614](#), [PMID:6825208](#), [PMID:6954533](#), [PMID:7523863](#), [PMID:9090379](#), [PMID:9220028](#), [PMID:9290701](#), [PMID:9842975](#), [PMID:10402232](#), [PMID:10416987](#), [PMID:10698499](#), [PMID:11351043](#), [PMID:14614447](#), [PMID:14655754](#), [PMID:15900046](#), [PMID:16232199](#), [PMID:16697959](#), [PMID:17254797](#), [PMID:17595512](#), [PMID:19365568](#), [PMID:19435942](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21406405](#), [PMID:22460905](#), [PMID:22570425](#), [PMID:23637631](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30188626](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:34036375](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: PTEN genetic alteration cell panel (ATCC TCP-1030)., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: A-172

Synonyms: A172, A 172, A-172 MG, A-172MG

Cross References: BTO:BTO_0000016, CLO:CLO_0001543, CLO:CLO_0001559, CLO:CLO_0001560, CLO:CLO_0050637, EFO:EFO_0002101, MCCL:MCC:0000023, CLDB:cl142, CLDB:cl143, CLDB:cl144, CLDB:cl146, AddexBio:C0005009/5018, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1620, ATCC:CRL-7899, BioGRID_ORCS_Cell_line:823, BioSample:SAMN03471115, BioSample:SAMN03471212, BioSample:SAMN03471659, BioSample:SAMN03471918, BioSample:SAMN10988258, cancercellines:CVCL_0131, CCRID:3101HUMTCHu171, Cell_Model_Passport:SIDM00799, CGH-DB:138-1, ChEMBL-Cells:ChEMBL3308491, ChEMBL-Targets:ChEMBL614512, CLS:300108, Cosmic:687563, Cosmic:849883, Cosmic:897446, Cosmic:1014068, Cosmic:1036334, Cosmic:1066233, Cosmic:1171223, Cosmic:1236360, Cosmic:1610751, Cosmic:1746956, Cosmic:1995327, Cosmic:2302321, Cosmic:2367506, Cosmic:2516012, Cosmic-CLP:687563, DepMap:ACH-000558, ECACC:88062428, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS225AJI, ENCODE:ENCBS874LTK, FANTOM5_SSTAR:10444-106F3, GDSC:687563, GEO:GSM101609, GEO:GSM101610, GEO:GSM326244, GEO:GSM886850, GEO:GSM887914, GEO:GSM1374378, GEO:GSM1669577, IARC_TP53:21157, ICLC:HTL97013, IGRhCellID:A172, IZSLER:BS TCL 2, JCRB:JCRB0228, KCB:KCB 200966YJ, KCLB:21620, LiGeA:CCLE_757, LINCS_LDP:LCL-1348, Lonza:178, NCBI_Iran:C211, PharmacDB:A172_36_2019, PRIDE:PXD001110, PRIDE:PXD030304, Progenetix:CVCL_0131, PubChem_Cell_line:CVCL_0131, RCB:RCB2530, TKG:TKG 0183, Wikidata:Q54605968

ID: CVCL_0131

Record Creation Time: 20220427T215104+0000

Record Last Update: 20260913T011850+0000

Ratings and Alerts

No rating or validation information has been found for A-172.

Warning: Discontinued: ATCC; CRL-7899

Population: Caucasian., Part of: PTEN genetic alteration cell panel (ATCC TCP-1030)., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 604 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Zhang Z, et al. (2026) B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression. *Molecular biomedicine*, 7(1).

Zhang Z, et al. (2026) Machine learning model on multi-omics data enables risk stratification and identifies molecular heterogeneity and therapeutic targets in glioblastoma. *Molecular cancer*, 25(1).

Fang C, et al. (2026) CUDC-907 inhibits glioblastoma and enhances glioblastoma sensitivity to temozolomide by inhibiting DNA damage repair. *Genes & diseases*, 13(5), 101948.

Kucwaj-Brysz K, et al. (2026) Spirohydantoin derivatives exert dopamine D2-like receptor-independent cytotoxicity in glioblastoma cells with possible involvement of calpain inhibition. *Scientific reports*, 16(1).

Song J, et al. (2026) JOSD1 Deubiquitinates Twist1 and Facilitates Epithelial-Mesenchymal Transition in Glioblastoma. *Cell biochemistry and function*, 44(4), e70208.

Sidhu RS, et al. (2026) Rap1b promotes glioma growth and stemness via regulation of Notch1 and VEGFR2 signaling pathways. *Cellular signalling*, 143, 112457.

Kempynck N, et al. (2026) CREsted: modeling genomic and synthetic cell-type-specific enhancers across tissues and species. *Nature methods*, 23(5), 946.

Krygier K, et al. (2026) A covalent peptide engager approach to equip immunotherapeutic monoclonal and pan IgG serum antibodies with new tumour-targeting function. *British journal of pharmacology*.

Beckner ME, et al. (2025) Cell Settling, Migration, and Stochastic Cancer Gene Expression Suggest Potassium Membrane Flux May Initiate pH Reversal. *Biomolecules*, 15(8).

Ramar V, et al. (2025) TRIM21 functions as an oncogene in glioblastoma by transactivating FOSL1 and promoting the ubiquitination of p27. *Cell communication and signaling : CCS*, 23(1), 313.

Guo S, et al. (2025) RNA Sequencing Identifies Novel Signaling Pathways and Potential Drug Target Genes Induced by FOSL1 in Glioma Progression and Stemness. *Biologics : targets & therapy*, 19, 157.

Schwarzenbach C, et al. (2025) Therapy-induced senescence of glioblastoma cells is determined by the p21CIP1-CDK1/2 axis and does not require activation of DREAM. *Cell death & disease*, 16(1), 357.

Yang M, et al. (2025) The alternatively spliced diacylglycerol kinase gamma-? exon13 transcript generated under hypoxia promotes glioblastoma progression. *Oncology research*, 33(5), 1189.

Knoll N, et al. (2025) CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer. *Cancer research*, 85(18), 3518.

Cornelissen FMG, et al. (2025) Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype. *Molecular cancer therapeutics*, 24(12), 1878.

Weber AF, et al. (2025) Downregulation of miR-27a-3p Modulates TGF- β Signaling and Dysregulates Metabolism in Glioblastoma. *International journal of molecular sciences*, 26(17).

Shin S, et al. (2025) mTOR inhibition reprograms cellular lipid homeostasis by inducing alternative lipid uptake and promoting cholesterol transport. *Molecular cell*, 85(18), 3486.

He X, et al. (2025) PI3K γ functions as a protein kinase to promote cellular protein O-GlcNAcylation and acetyl-CoA production for tumor growth. *Molecular cell*, 85(7), 1411.

Yang H, et al. (2025) 7 I, a structurally modified sinomenine, exerts dual anti-GBM effects by inhibiting glioblastoma proliferation and inducing necroptosis which further mediates lysosomal cell death. *British journal of pharmacology*, 182(10), 2310.

Chen K, et al. (2025) Ferroptosis resistance-related TEP1 as a novel prognostic biomarker involved in immune cell infiltration and tumour progression in glioblastoma. *Cancer cell international*, 26(1), 14.